The dopamine receptor agonist apomorphine stabilizes neurotoxic α-synuclein oligomers

被引:2
|
作者
Lima, Vanderlei de Araujo [1 ,2 ]
Esquinelato, Rodrigo [1 ]
Carmo-Goncalves, Phelippe [1 ,2 ]
do Nascimento, Lucas Alex [1 ]
Lee, Hudson [3 ]
Eliezer, David [3 ]
Romao, Luciana [4 ]
Follmer, Cristian [1 ,2 ]
机构
[1] Univ Fed Rio de Janeiro, Dept Phys Chem, BR-21941909 Rio De Janeiro, Brazil
[2] Univ Fed Rio de Janeiro, Inst Chem, Grad Program Chem, Rio De Janeiro, Brazil
[3] Cornell Univ, Weill Cornell Med Coll, Dept Biochem, New York, NY USA
[4] Univ Fed Rio de Janeiro, Inst Biomed Sci, Rio De Janeiro, Brazil
基金
美国国家卫生研究院;
关键词
apomorphine; dopamine; neurotoxicity; oligomer; Parkinson's disease; alpha-synuclein; PARKINSONS-DISEASE; AMYLOID-BETA; MOTOR RESPONSE; IN-VIVO; FIBRILS; AGGREGATION; MODEL; PHARMACOKINETICS; TRANSMISSION; DYSFUNCTION;
D O I
10.1002/1873-3468.14263
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The misfolding and aggregation of the protein alpha-synuclein (aSyn) into potentially neurotoxic oligomers is believed to play a pivotal role in the neuropathogenesis of Parkinson's disease (PD). Herein, we explore how apomorphine (Apo), a nonselective dopamine D1 and D2 receptor agonist utilized in the therapy for PD, affects the aggregation and toxicity of aSyn in vitro. Our data indicated that Apo inhibits aSyn fibrillation leading to the formation of large oligomeric species (Apo-aSyn-O), which exhibit remarkable toxicity in mesencephalic dopaminergic neurons in primary cultures. Interestingly, purified Apo-aSyn-O, even at very low concentrations, seems to be capable of converting unmodified aSyn monomer into neurotoxic species. Collectively, our findings warn for a possible dangerous effect of Apo on aSyn misfolding/aggregation pathway.
引用
收藏
页码:309 / 322
页数:14
相关论文
共 50 条
  • [41] THE EFFECTS OF INTRACRANIAL ADMINISTRATION OF THE DOPAMINE AGONIST APOMORPHINE ON PENILE REFLEXES AND SEMINAL EMISSION IN THE RAT
    PEHEK, EA
    THOMPSON, JT
    HULL, EM
    BRAIN RESEARCH, 1989, 500 (1-2) : 325 - 332
  • [42] Differences in multihormonal responses to the dopamine agonist apomorphine between unipolar and bipolar depressed patients
    Antonio Monreal, Jose
    Duval, Fabrice
    Mokrani, Marie-Claude
    Fattahe, Said
    Palao, Diego
    JOURNAL OF PSYCHIATRIC RESEARCH, 2019, 112 : 18 - 22
  • [43] EFFECTS OF AN INTRATHECAL DOPAMINE AGONIST, APOMORPHINE, ON THERMAL AND CHEMICAL EVOKED NOXIOUS RESPONSES IN RATS
    JENSEN, TS
    YAKSH, TL
    BRAIN RESEARCH, 1984, 296 (02) : 285 - 293
  • [44] THE EFFECT OF THE DOPAMINE AGONIST, APOMORPHINE, ON REGIONAL CEREBRAL BLOOD-FLOW IN NORMAL VOLUNTEERS
    GRASBY, PM
    FRISTON, KJ
    BENCH, CJ
    COWEN, PJ
    FRITH, CD
    LIDDLE, PF
    FRACKOWIAK, RSJ
    DOLAN, RJ
    PSYCHOLOGICAL MEDICINE, 1993, 23 (03) : 605 - &
  • [45] Dopamine promotes formation and secretion of non-fibrillar alpha-synuclein oligomers
    He-Jin Lee
    Sung Min Baek
    Dong-Hwan Ho
    Ji-Eun Suk
    Eun-Duk Cho
    Seung-Jae Lee
    Experimental & Molecular Medicine, 2011, 43 : 216 - 222
  • [46] Dopamine promotes formation and secretion of non-fibrillar alpha-synuclein oligomers
    Lee, He-Jin
    Baek, Sung Min
    Ho, Dong-Hwan
    Suk, Ji-Eun
    Cho, Eun-Duk
    Lee, Seung-Jae
    EXPERIMENTAL AND MOLECULAR MEDICINE, 2011, 43 (04): : 216 - 222
  • [47] Dopamine-Induced Oligomers of α-Synuclein Inhibit Amyloid Fibril Growth and Show No Toxicity
    Galkin, Maksym
    Topcheva, Oleksandra
    Priss, Anastasiia
    Borisova, Tatiana
    Shvadchak, Volodymyr V.
    ACS CHEMICAL NEUROSCIENCE, 2023, 14 (11): : 2027 - 2034
  • [48] Structural determinants of Dopamine Receptor Agonist selectivity
    Trovato, O.
    Baumann, J.
    Posch, M.
    Seidl, S.
    Lechuga, A.
    Henninger, M.
    Abt, L.
    Langeslag, M.
    Lieb, A.
    Kaserer, T.
    Thaler, G.
    Bauer, M.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2024, 397 : S55 - S55
  • [49] PHARMACODYNAMICS OF A NEW DOPAMINE (DA) RECEPTOR AGONIST
    SCHILLING, JC
    ADAMUS, WS
    LEONARD, JP
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 47 (02) : 167 - 167
  • [50] Talipexole, a dopamine receptor agonist, in the treatment of glaucoma
    Widmann, R
    Trach, V
    Rozman, T
    VISION RESEARCH, 1996, 36 : 34 - 34